donafenib   Click here for help

GtoPdb Ligand ID: 11830

Synonyms: CM-4307 | CM4307 | Sorafenib-d3 | Zepsun®
Compound class: Synthetic organic
Comment: Donafenib (CM-4307) is a deuterated derivative of the approved multikinase inhibitor sorafenib. Like sorafenib, it is orally active. Deuteration improves the stability of drug molecules thus extending half-life and increasing systemic exposure. This means that the effective drug dose may be shifted downward, with an associated improvement in tolerability. The medical formulation is donafenib tosylate.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 92.35
Molecular weight 464.09
XLogP 3.75
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=C(Nc1ccc(c(c1)C(F)(F)F)Cl)Nc1ccc(cc1)Oc1ccnc(c1)C(=O)NC([2H])([2H])[2H]
Isomeric SMILES C([2H])([2H])([2H])NC(=O)c1nccc(c1)Oc1ccc(cc1)NC(=O)Nc1cc(c(cc1)Cl)C(F)(F)F
InChI InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)/i1D3
InChI Key MLDQJTXFUGDVEO-FIBGUPNXSA-N
No information available.
Summary of Clinical Use Click here for help
Donafenib (CM-4307) was progressed to clinical evaluations to determine its efficacy against advanced solid tumours. It exhibited superior overall survival results compared to sorafenib in a direct comparison study in patients with unresectable/metastatic hepatocellular carcinoma [3]. Donafenib was granted its first international approval in China (June 2021) [1]. This approval indicated donafenib as a first-line systemic therapy for unresectable hepatocellular carcinoma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05138159 A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen Phase 2 Interventional Fudan University
NCT02645981 Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma Phase 2/Phase 3 Interventional Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT02229071 Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma Phase 1/Phase 2 Interventional Suzhou Zelgen Biopharmaceuticals Co.,Ltd 2